Navigation Links
Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
Date:5/13/2010

HOBOKEN, N.J., May 13 /PRNewswire/ -- Octapharma USA today announced that wilate®, the first replacement therapy development specifically for von Willebrand Disease (VWD), is now available from the biopharmaceutical company's authorized distributors. The U.S. Food and Drug Administration (FDA) has approved wilate® for the treatment of spontaneous or trauma-induced bleeding episodes in patients with severe VWD as well as in patients with mild or moderate forms of the illness in whom the use of desmopressin is known or suspected to be ineffective or contraindicated.

(Photo: http://www.newscom.com/cgi-bin/prnh/20100513/NY04210 )

"Wilate® is an innovative treatment option for patients with von Willebrand disease that offers a high purity VWF/FVIII complex with a physiologic ratio of FVIII and VWF, double virus inactivation, convenient dosing, and clinical efficacy, safety, and tolerability proven in adult and pediatric populations," said Flemming Nielsen, President of Octapharma USA, the rapidly growing U.S. division of Octapharma AG, one of the largest plasma products manufacturers in the world. "We are pleased to be partnering with distributors who are committed to providing medical professionals with the therapies patients need in a timely, cost-effective manner."

The list of authorized distributors of wilate® are available at www.wilateusa.com.

According to the National Institutes of Health (NIH), VWD is the most common inherited bleeding disorder and occurs in about 1 out of every 100 to 1,000 people.

About the Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma is one of the largest plasma products manufacturers in the world and has been committed to patient care and medical innovation for over 25 years. Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam® (immune globulin intravenous [human] 5%), is used to treat disorders of the immune system, and Octapharma's albumin (Human) is indicated for the restoration and maintenance of circulating blood volume. Octapharma's wilate® was approved by the U.S. Food and Drug Administration (FDA) for the treatment of von Willebrand disease (VWD). Octapharma employs over 3,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, N.J. Octapharma operates two state-of-the-art production sites licensed by the FDA, providing a high level of production flexibility. For more information, please visit www.octapharma.com.

Forward-looking statements

This news release contains forward-looking statements, which include known and unknown risks, uncertainties and other factors not under the company's control. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. These factors include results of current or pending research and development activities and actions by the FDA or other regulatory authorities.


'/>"/>
SOURCE Octapharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
2. Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
3. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
4. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
5. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
6. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
7. Cogdell Spencer Announces Commencement of Common Stock Offering
8. Mylan Announces Upsizing and Pricing of Senior Notes
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Baird Growth Stock Conference
10. Stereotaxis Announces Vdrive(TM), a New Technology for Remote Navigation of Diagnostic Devices
11. WuXi PharmaTech Announces First-Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 9, 2016 The life of Dr. Jan ... been anything but ordinary.  Twists of fate, combined with sheer ... and the constraints of communist Czechoslovakia to New ... go on to make history by playing a key role ... in the world, Remicade.  Dr. Vilcek brings readers along his ...
(Date:2/9/2016)... 2016  Bluestar Silicones will promote its Silbione® ... long-term implant applications and announce certification of its ... (MD&M) West Conference (Booth #1759), February 9-10, at ... --> Available in 01 through ... outstanding physical properties enabling our customers to optimize ...
(Date:2/8/2016)... Cardiovascular Surgery Devices - Medical Devices Pipeline Assessment, ... report, "Cardiovascular Surgery Devices - Medical Devices Pipeline ... Devices currently in pipeline stage. ... comprehensive information on the pipeline products with comparative ... development. The report reviews major players involved in ...
Breaking Medicine Technology:
(Date:2/8/2016)... GA (PRWEB) , ... February 08, 2016 , ... Coast ... cavity-free. February is National Children’s Dental Health Month and family dentist Yvonne Dorrian, DMD, ... p.m. at Coast Dental , located next to Target at 1207 North Peachtree ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... The Valentine’s Season is famous for gift ... and significant others that they are loved. This year, for more than 5.6 million ... cost - just won't be enough to remind them of the lives they’ve led and ...
(Date:2/8/2016)... ... February 08, 2016 , ... Brenton Engineering , ... bags, and flow wrapped products at WestPack 2015, February 9-11, in Anaheim, California. ... up to semi-automatic or fully-automatic case packing with a small footprint, rugged, highly ...
(Date:2/8/2016)... ... February 08, 2016 , ... Tingley ... into Canada to provide its range of unique and advantaged protective solutions ... City that will provide bilingual customer service and marketing support. A new distribution ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Bell Agency, a ... latest beneficiary of their ongoing community enrichment program. The current campaign fundraises for ... Donations are now being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & Doves ...
Breaking Medicine News(10 mins):